Login to Your Account



Chaperone Trips on LSD

Amicus' Amigal Moves Forth as Plicera Falters in Phase II

By Randy Osborne


Tuesday, October 6, 2009
Amicus Therapeutics Inc.'s bad preliminary news with Plicera from a small Phase II study in Gaucher disease "does advance the general proof of concept of chaperones" despite the failure, CEO John F. Crowley told investors during an aftermarket conference call Friday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription